Date: 2013-01-31
Type of information: R&D agreement
Compound:
Company: Antitope (UK) Rottapharma Biotech (Italy)
Therapeutic area: Musculoskeletal diseases
Type agreement: R&D
Action mechanism:
Disease: musculoskeletal disorders
Details: * On January 31, 2013, Antitope has announced the completion of a research collaboration with Rottapharma Biotech Srl, the Antibody Research Unit of the Italian healthcare company Rottapharm|Madaus, whereby Antitope applied is proprietary EpiScreen™ and in silico iTope™/TCED™ technologies to profile the immunogenicity of therapeutic antibodies as a part of Rotapharm Biotech Srl research and development program in the field of musculoskeletal disorders.
Financial terms:
Latest news:
